Ann: Change of Registry Address, page-3

The broker who accumulated the stock now makes sure this stays at the same price range
and does not fall on bad market sentiment.

Management has stepped away from a quick cash in with US investors to first establish
further platform evaluations ( what many OZ investors had hoped for, but ruining the much larger game to meet those same investors next year with platform intact ), let the stock appreciate towards clinical trials with the help of an OZ fund commitment and then approach the Americans again, from a position of strength.

Check other biotech partnership deals and the lull at trading prior to the event.
This takes a very special kind of investor to be prepared to endure this, knowledge though
helps to see this through.
Rewards in biotech can be massive once the game plan comes through.

Many here waited for 10 years plus, the onset of clinical trials and platform extension
will see a strong SP performance. Whether this to happen early or mid 2022 is probably for most here secondary.
All research and milestones achieved point towards that event.

Just imagine a cancer vaccine to be developed with a PYC library peptide for delvery,
on top of ocular, CNS and kidney platform....
Mind boggling and worth waiting for.

all IMO